Fact CheckerSign in

NCT06331195Active, not recruiting

An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)

Effects of an Adapted Brazilian Cardioprotective Diet Supplemented or Not With Phytosterols and/or Krill Oil in Patients With Familial Hypercholesterolemia: the DICA-FH Randomized Clinical Trial

Source: ClinicalTrials.gov · Last updated 12 May 2026

Brief summary (registry, in English)

The main objective of this randomized clinical trial is to evaluate the effects of the adapted Brazilian Cardioprotective Diet (DICA Br) supplemented or not with phytosterols and/or krill oil in patients with a probable or definitive diagnosis of familial hypercholesterolemia (FH) according to the the Dutch Lipid Clinic Network (Dutch MEDPED) criteria. In addition, the following will be considered secondary objectives: to perform participants´ whole genome sequencing (WGS); to evaluate the effects of the interventions on lipid profile biomarkers; to evaluate the frequency of mild, moderate and severe adverse events according to study groups; and to evaluate adherence rates according to study groups. In this study, 300 individuals will be randomly enrolled into four groups: 1) DICA Br adapted to the FH context (DICA-FH) + phytosterol placebo + krill oil placebo (control group); 2) DICA-FH + 2g/day of phytosterol + krill oil placebo; 3) DICA-FH + phytosterol placebo + 2g/day of krill oil; and 4) DICA-FH + 2g/day of phytosterol + 2g/day of krill oil. Primary outcomes will be LDL-cholesterol for groups phytosterol vs. placebo and lipoprotein(a) for groups krill oil vs. placebo after 120 days of follow up.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
300 (estimated)
First submitted
19 Mar 2024
Start date
23 Oct 2024
Primary completion date
13 Feb 2026
Lead sponsor
Hospital do Coracao
NCT number
NCT06331195

What you commit to

  • Study type: Interventional
  • Planned participants: 300
  • From 23 Oct 2024 to the primary completion date, 13 Feb 2026
  • 24 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • TG ≥ 500mg/dL up to 6 months before screening for the study;
  • HIV positive on treatment with detectable viral load or AIDS;
  • Chronic use of anti-inflammatories, anticonvulsants and immunosuppressive drugs;
  • Use of PCSK9 inhibitors (alirocumab, evolocumab, inclisiran);

Other illness

  • Food allergies (foods, dyes, preservatives);
  • Chronic inflammatory or autoimmune diseases;
  • Known liver disease, chronic kidney disease on dialysis or pancreatitis (acute and chronic);
  • Cancer being treated or life expectancy \< 6 months;
  • Episode of acute coronary syndrome in the last 60 days;
  • Refusal to participate in the study, due to failure to sign the Free and Informed Consent Form.

Age

  • Grade III/severe obesity (body mass index \[BMI\] ≥40kg/m² for adults or percentile \>99.9 or z-score \>+3 according to WHO/2006 growth curves for BMI/Age indicator for adolescents);

Other

  • Having a "possible" FH result according to the Dutch MEDPED criteria;
  • Diagnosis of hypercholesterolemia due to a secondary cause recorded in the medical record;
  • Contraindication to the use of phytosterols (for example: diagnosis of sitosterolemia);
  • Chemical dependency/alcoholism;
  • Pregnancy or lactation;
  • Individuals who are unable to perform an anthropometric assessment, at the discretion of the investigator;
  • Use of dietary supplements that may interfere with the outcomes of interest (dietary fiber modules, n-3 PUFA, essential fatty acids);
  • Participation in other randomized clinical trials;

Who the study is looking for

  • Age ≥16 years;
  • Definitive (certainty) or probable diagnosis of FH by the Dutch MEDPED criteria;
  • Using one of the following treatment regimens for ≥6 weeks according to age:
    • \>= 20 years -\> simvastatin 40 mg; lovastatin 40 mg; pravastatin 80 mg; atorvastatin 20 mg; rosuvastatin 10 mg; pitavastatin 4 mg; fluvastatin 80 mg; atorvastatin 40- 80 mg; rosuvastatin 20 - 40 mg; atorvastatin 40 - 80 mg + ezetimibe 10mg; rosuvastatin 20 - 40 mg + ezetimibe 10mg; or simvastatin 40mg + ezetimibe 10mg.
    • 16 to 19 years -\> simvastatin 10 - 40 mg; lovastatin 10 - 40 mg; pravastatin 10 - 40 mg; atorvastatin 10 - 40 mg; rosuvastatin 5 - 40 mg; cholestyramine 4 to 16 mg; ezetimibe 10mg (in combination with statin).

Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (24)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
OCARA
Coordinator of this site? Confirm its status
BelémBrazilUnknown status
Centro Oncologico de Roraima
Coordinator of this site? Confirm its status
Boa VistaBrazilUnknown status
Instituto de Cardiologia e Transplantes do DF
Coordinator of this site? Confirm its status
BrasíliaBrazilUnknown status
Universidade do Mato Grosso do Sul
Coordinator of this site? Confirm its status
Campo GrandeBrazilUnknown status
Universidade Federal do Mato Grosso
Coordinator of this site? Confirm its status
CuiabáBrazilUnknown status
Hospital Oto Aldeota
Coordinator of this site? Confirm its status
FortalezaBrazilUnknown status
Universidade Federal de Goias
Coordinator of this site? Confirm its status
GoiâniaBrazilUnknown status
Universidade Federal do Amapá
Coordinator of this site? Confirm its status
MacapáBrazilUnknown status
Centro de Pesquisas Clínicas Dr. Marco Mota
Coordinator of this site? Confirm its status
MaceióBrazilUnknown status
Universidade Federal do Amazonas
Coordinator of this site? Confirm its status
ManausBrazilUnknown status
Universidade Estadual de Maringá
Coordinator of this site? Confirm its status
MaringáBrazilUnknown status
Santa Casa de Montes Claros
Coordinator of this site? Confirm its status
Montes ClarosBrazilUnknown status
Centro de Estudos e Pesquisas em Moléstias Infecciosas
Coordinator of this site? Confirm its status
NatalBrazilUnknown status
Universidade Federal do Tocantins
Coordinator of this site? Confirm its status
PalmasBrazilUnknown status
Universidade Federal do Vale do São Francisco
Coordinator of this site? Confirm its status
PetrolinaBrazilUnknown status
Instituto de Pesquisa e Ensino em Saúde
Coordinator of this site? Confirm its status
Porto VelhoBrazilUnknown status
Centro de Pesquisa Silvestre Santé
Coordinator of this site? Confirm its status
Rio BrancoBrazilUnknown status
Instituto Nacional de Cardiologia
Coordinator of this site? Confirm its status
Rio de JaneiroBrazilUnknown status
Hospital Ana Nery
Coordinator of this site? Confirm its status
SalvadorBrazilUnknown status
INCOR
Coordinator of this site? Confirm its status
São PauloBrazilUnknown status
Universidade Federal de Sao Paulo
Coordinator of this site? Confirm its status
São PauloBrazilUnknown status
Instituto Dante Pazzanese de Cardiologia
Coordinator of this site? Confirm its status
São PauloBrazilUnknown status
Hcor
Coordinator of this site? Confirm its status
São PauloBrazilUnknown status
Centro de Pesquisa Cardiolima
Coordinator of this site? Confirm its status
TeresinaBrazilUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.